Paul Choi
Stock Analyst at Goldman Sachs
(3.28)
# 961
Out of 5,182 analysts
106
Total ratings
52.24%
Success rate
1.24%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $8.80 | +36.36% | 4 | Feb 10, 2026 | |
| VERA Vera Therapeutics | Maintains: Buy | $55 → $95 | $45.04 | +110.92% | 1 | Dec 19, 2025 | |
| CYTK Cytokinetics | Upgrades: Buy | $55 → $95 | $65.01 | +46.13% | 3 | Dec 19, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $68.69 | -27.21% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $74.59 | +34.07% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $47.08 | +16.82% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $10.82 | -44.55% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $80.59 | -4.45% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $32.82 | -39.06% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $44.27 | +6.17% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $7 → $12 | $14.48 | -17.13% | 9 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $3 | $21.57 | -86.09% | 4 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $0.41 | +1,853.60% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $12.63 | -60.41% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $58.40 | -10.96% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $9.50 | +121.05% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $2.17 | +38.25% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $239.28 | -5.97% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $15.24 | +24.67% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.59 | +313.94% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.32 | +1,801.14% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $9.18 | +1,751.85% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $7.78 | +2.83% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $128.89 | +4.74% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $77.50 | +287.10% | 2 | Mar 30, 2020 |
REGENXBIO
Feb 10, 2026
Maintains: Neutral
Price Target: $14 → $12
Current: $8.80
Upside: +36.36%
Vera Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $95
Current: $45.04
Upside: +110.92%
Cytokinetics
Dec 19, 2025
Upgrades: Buy
Price Target: $55 → $95
Current: $65.01
Upside: +46.13%
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $68.69
Upside: -27.21%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $74.59
Upside: +34.07%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $47.08
Upside: +16.82%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $10.82
Upside: -44.55%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $80.59
Upside: -4.45%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $32.82
Upside: -39.06%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $44.27
Upside: +6.17%
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $14.48
Upside: -17.13%
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $21.57
Upside: -86.09%
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $0.41
Upside: +1,853.60%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $12.63
Upside: -60.41%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $58.40
Upside: -10.96%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $9.50
Upside: +121.05%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $2.17
Upside: +38.25%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $239.28
Upside: -5.97%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $15.24
Upside: +24.67%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.59
Upside: +313.94%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.32
Upside: +1,801.14%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $9.18
Upside: +1,751.85%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $7.78
Upside: +2.83%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $128.89
Upside: +4.74%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $77.50
Upside: +287.10%